Drug
Orelabrutinib R Chop
Orelabrutinib R Chop: highest development phase Phase 3, developed by InnoCare Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Orelabrutinib + R-CHOP NCT05234684 | Phase 3 | Diffuse Large B Cell Lymphoma (DLBCL) |
Latest
No recent events.
Follow Orelabrutinib R Chop on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.